Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies is pleased to announce a new licensing venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR).

Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression. Detailed product information can be found at https://rockland-inc.com/limr-collaboration.aspx. George Prendergast, PhD, President and CEO of LIMR, stated, “We are proud of the achievement of LDI to generate an agreement with Rockland to commercialize the high-quality research antibodies developed at LIMR.”

“LIMR’s work in cancer and inflammation is an elegant fit with Rockland’s antibody portfolio and technology platform. We partner with leading institutions to bring to researchers the reagents vital to the advance of their key research. The Philadelphia region is home to some of the world’s finest research centers. We are proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community,” commented James Fendrick, President and CEO of Rockland Immunochemicals.

About Rockland Immunochemicals

Rockland Immunochemicals has supported the research, biopharma and diagnostic industries for over 50 years with the highest quality antibodies and antibody based tools. Rockland is engaged in the development of new technologies for the production of antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA, and FLOW cytometry.

More information about Rockland Immunochemicals and its products and services can be found at the company’s web site at www.rockland-inc.com.

About LIMR Development, Inc.

LIMR Development, Inc. (LDI) is the business development subsidiary of Lankenau Institute for Medical Research (LIMR). Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, non-profit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Medical Center. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease and diabetes. For information about LIMR, please visit www.limr.org.